MedWatch http://medwatch.dk/ MedWatch da Copyright 2012, MedWatch Tue, 27 Jun 2017 12:30:54 GMT MedWatch - seneste nyt MedWatch - seneste nyt medwatch.dk 2017-06-27T12:30:54Z da Copyright 2012, MedWatch MedWatch http://medwatch.dk/mwimg/logo/main_logo.png http://medwatch.dk/ Goodbye to Novo A/S http://medwatch.dk/secure/Top_picks_in_english/article9683261.ece?utm_source=Feed&utm_medium=latest In order to avoid confusion, Novo A/S, the holding company of Novo Nordisk and Novozymes and one of Denmark’s major life science investors, has decided to change its name. Top picks in English Tue, 27 Jun 2017 12:30:54 GMT http://medwatch.dk/secure/Top_picks_in_english/article9683261.ece?utm_source=Feed&utm_medium=latest BY ELIZABETH MØNSTED JOHANSEN 2017-06-27T12:30:54Z true FDA panel sees cardiovascular benefits from Novo's Victoza http://medwatch.dk/secure/Top_picks_in_english/article9668881.ece?utm_source=Feed&utm_medium=latest With an overwhelming majority, an independent advisory committee under the US drug agency FDA has found that Novo Nordisk’s Leader study provides substantial evidence of cardiovascular risk reduction in treatment with Victoza. The result opens up the opportunity for including the data on the product’s US label. Top picks in English Wed, 21 Jun 2017 19:56:20 GMT http://medwatch.dk/secure/Top_picks_in_english/article9668881.ece?utm_source=Feed&utm_medium=latest BY MARTIN HAVTORN PETERSEN 2017-06-21T19:56:20Z true Zealand sees big potential for SBS drug http://medwatch.dk/secure/Top_picks_in_english/article9666453.ece?utm_source=Feed&utm_medium=latest Zealand Pharma sees a significant potential for the candidate drug glepaglutide for treatment of short bowel syndrome (SBS), which has just delivered promising phase II results. The biotech company plans to win approval and market the drug on its own, hoping it can compete with a similar product from Shire, says CEO Britt Meelby Jensen. Top picks in English Wed, 21 Jun 2017 19:54:42 GMT http://medwatch.dk/secure/Top_picks_in_english/article9666453.ece?utm_source=Feed&utm_medium=latest BY MARTIN HAVTORN PETERSEN 2017-06-21T19:54:42Z true Lundbeck Foundation company goes public http://medwatch.dk/secure/Top_picks_in_english/article9669314.ece?utm_source=Feed&utm_medium=latest Lundbeckfonden Ventures’ portfolio company Bonesupport has listed on the Swedish stock market and raised SEK 500 million (about USD 57 million). The IPO puts a period to a busy half year, where two other companies have been sold. New investments are coming up, says managing partner Mette Kirstine Agger. Top picks in English Wed, 21 Jun 2017 19:45:07 GMT http://medwatch.dk/secure/Top_picks_in_english/article9669314.ece?utm_source=Feed&utm_medium=latest BY LONNI PARK LYNGE 2017-06-21T19:45:07Z true Onxeo raises EUR 15m in stock offering http://medwatch.dk/secure/Top_picks_in_english/article9669589.ece?utm_source=Feed&utm_medium=latest The French-Danish biotech company Onxeo has raised EUR 15 million (USD 16.73 million) in a recently completed capital increase. The goal was EUR 12 million (USD 13.39 million), but the fundraising brought the company’s management a pleasant surprise. Top picks in English Wed, 21 Jun 2017 19:04:23 GMT http://medwatch.dk/secure/Top_picks_in_english/article9669589.ece?utm_source=Feed&utm_medium=latest BY LEONORA BECK & RITZAU FINANS 2017-06-21T19:04:23Z true Leo Pharma invests in US biotech company http://medwatch.dk/secure/Top_picks_in_english/article9668509.ece?utm_source=Feed&utm_medium=latest The Danish dermatology company Leo Pharma has pumped money into a US based biotech company developing a medical device mainly to be used in treatments of a hair loss disease. It is also the first agreement made from Leo’s newly founded hub in Boston. Top picks in English Wed, 21 Jun 2017 09:18:01 GMT http://medwatch.dk/secure/Top_picks_in_english/article9668509.ece?utm_source=Feed&utm_medium=latest BY ELIZABETH MØNSTED JOHANSEN 2017-06-21T09:18:01Z true Genmab’s cash cow obtains new approval http://medwatch.dk/secure/Top_picks_in_english/article9665520.ece?utm_source=Feed&utm_medium=latest FDA has added a new indication to the list for Genmab’s successful cancer drug Darzalex. The Danish biotech company can now look forward to a sizeable milestone payment. Top picks in English Tue, 20 Jun 2017 13:13:35 GMT http://medwatch.dk/secure/Top_picks_in_english/article9665520.ece?utm_source=Feed&utm_medium=latest BY LEONORA BECK 2017-06-20T13:13:35Z true Zealand’s SBS drug shows promising phase II results http://medwatch.dk/secure/Top_picks_in_english/article9665822.ece?utm_source=Feed&utm_medium=latest Zealand Pharma’s candidate drug glepaglutide has met the primary endpoint in a phase II study testing it as a treatment of short bowel syndrome (SBS). Phase III trials can begin next year. Top picks in English Tue, 20 Jun 2017 12:51:55 GMT http://medwatch.dk/secure/Top_picks_in_english/article9665822.ece?utm_source=Feed&utm_medium=latest BY MARTIN HAVTORN PETERSEN 2017-06-20T12:51:55Z true Swedish company fails in study of diabetes vaccine http://medwatch.dk/secure/Top_picks_in_english/article9665740.ece?utm_source=Feed&utm_medium=latest In a study with children at risk of developing type 1 diabetes, an experimental vaccine from Sweden's Diamyd Medical has failed to show a significant difference from placebo. The result cut off more than 20 percent of the company’s share price in just two days. Top picks in English Tue, 20 Jun 2017 12:46:07 GMT http://medwatch.dk/secure/Top_picks_in_english/article9665740.ece?utm_source=Feed&utm_medium=latest BY MARTIN HAVTORN PETERSEN 2017-06-20T12:46:07Z true Zealand CEO: cancelled agreement is positive news http://medwatch.dk/secure/Top_picks_in_english/article9651201.ece?utm_source=Feed&utm_medium=latest Swiss drug group Helsinn has returned the rights to a Zealand-developed drug to the Danish company and thus, cancelled an almost nine year old license agreement. However, Zealand’s CEO Britt Meelby Jensen is far from pessimistic. Top picks in English Wed, 14 Jun 2017 18:42:27 GMT http://medwatch.dk/secure/Top_picks_in_english/article9651201.ece?utm_source=Feed&utm_medium=latest BY MARTIN HAVTORN PETERSEN 2017-06-14T18:42:27Z true Devote data can give Novo more negotiation power http://medwatch.dk/secure/Top_picks_in_english/article9651755.ece?utm_source=Feed&utm_medium=latest Detailed data from Novo Nordisk’s comparative Devote study confirms that the company’s new insulin is as safe as and markedly more effective than its rival, the top-selling Lantus from Sanofi. This information can strengthen Novo’s position in the important ongoing negotiations with US payers. Top picks in English Wed, 14 Jun 2017 18:34:21 GMT http://medwatch.dk/secure/Top_picks_in_english/article9651755.ece?utm_source=Feed&utm_medium=latest BY MARTIN HAVTORN PETERSEN 2017-06-14T18:34:21Z true IBM to develop artificial intelligence for Danish healthcare system http://medwatch.dk/secure/Top_picks_in_english/article9651361.ece?utm_source=Feed&utm_medium=latest The Capital Region of Denmark has budgeted DKK 30 million (USD 4.53 million) for developing artificial intelligence to the public health authorities in collaboration with IBM. Top picks in English Wed, 14 Jun 2017 18:11:07 GMT http://medwatch.dk/secure/Top_picks_in_english/article9651361.ece?utm_source=Feed&utm_medium=latest BY LEONORA BECK 2017-06-14T18:11:07Z true Sweden’s Oasmia aims to raise nearly USD 19m http://medwatch.dk/secure/Top_picks_in_english/article9648241.ece?utm_source=Feed&utm_medium=latest The executive board of Oasmia Pharmaceutical has resolved to carry out an issue of shares in order to raise millions for development, production and debt installments. Top picks in English Wed, 14 Jun 2017 18:04:42 GMT http://medwatch.dk/secure/Top_picks_in_english/article9648241.ece?utm_source=Feed&utm_medium=latest BY MIKKEL AABENHUS HEMMINGSEN 2017-06-14T18:04:42Z true